Celltrion, Inc. and Celltrion Healthcare Co., Ltd. each respectively held a General Meeting of Shareholders on October 23th, 2023 wherein resolutions were adopted under which Celltrion Healthcare Co., Ltd. shall be absorbed by and merged into Celltrion, Inc., and therefore, Celltrion, Inc. shall remain as the surviving company and Celltrion Healthcare Co., Ltd shall be dissolved and become non-existent. Upon the merger, Celltrion, Inc. shall assume from Celltrion Healthcare Co., Ltd any and all of its rights and obligations.
Pursuant to Article 527-5 of the Korean Commercial Code, we request that any creditor having objection to the above please submit his/her objection as set forth below:
1. Period of submission for objection: October 24th, 2023 ~ November 24th, 2023
2. Submission address: 4th Fl, 19, Academy-ro 51beon-gil, Yeonsu-gu, Incheon, Republic of Korea
3. Other inquiries: merger-project@celltrionhc.com
October 24th, 2023
Celltrion Healthcare Co., Ltd
4th Fl, 19, Academy-ro 51beon-gil, Yeonsu-gu, Incheon, Republic of Korea
Representative Director, Hyoung Ki Kim